chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient received the Moderna COVID-19 vaccine on 3/22/21 at a different clinic, then came to a different clinic and received a Pfizer COVID-19 vaccination on 4/19/21.  The patient failed to inform the vaccinators that the first dose he received was Moderna and came to a second dose Pfizer clinic.
Swelling under the armpit of arm; painful and prevents the arm from moving; painful and prevents the arm from moving; This is a spontaneous report of a contactable consumer (patient) by a Pfizer colleague through a program. A 58-Year-old female consumer received the doses 1 of bnt162b2 (PFIZER-BIONTECH mRNA COVID-19 VACCINE, Solution for injection) via an unspecified route of administration in arm right, administered on 07Apr2021 at 14:30 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history includes Type 1 Diabetic, pressure (increased blood pressure) and allergic to penicillin. Concomitant medications were not reported. It was reported that on 08Apr2021 at 05:00 pm patient experienced swelling under the armpit of arm where vaccine was administered, and It was painful and prevents the arm from moving. The patient was not pregnant at the time of vaccination. The patient did not do a test Covid post vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any treatment for the events. Patient did not receive any other vaccine in four weeks. Outcome of the events was not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
I experienced a fever of 101.5 around 24 hours after receiving the vaccine, which stayed with me for 4 days- going as high as 104.5. I was able to control with Tylenol/ Motrin, but fever did not go below 101.0 for the 4 days I was bedridden. I also experienced the following: Overall feeling of unwellness, Headache, chills, aches, sore injection site, weakness, nausea, severe diarrhea with bile, and coughing
her arm hurt/burning/arm still hurts and cannot move arm; couldn't move her arm; her arm hurt/burning; fever; headache; stomach ache; This is a spontaneous report from a contactable Nurse via Pfizer sales representative. A female patient of an unspecified age received meningococcal group b rlp2086 (TRUMENBA), dose 2 via an unspecified route of administration, administered in Arm on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE for immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, patient received 2nd dose of Trumenba Monday, almost instant her arm hurt/burning. Next day she had fever, headache, stomach ache and couldn't move her arm. Today arm still hurts and cannot move arm. The outcome of the events pain in arm and movement disorder was not recovered, other events was unknown.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained. No further information is expected.
COVID 19 Treatment; COVID 19 Treatment; Dose 1: Pfizer/Dose 2: Pfizer/Dose 3: Pfizer/Dose 4: Moderna/Dose 5: Moderna; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old male patient received bnt162b2 (BNT162B2), on 29Mar2021 as dose 1, single (Lot number: ER8732), in left arm, on 31Jul2021 as dose 2, single (Lot number: EW0161), in left arm and on 12Nov2021 as dose 3 (booster), single (Lot number: FH8030) at the age of 59 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 25May2022 as dose 4 (booster), single (Lot number: 059M21A), in left arm and on 21Sep2022 as dose 5 (booster), single (Lot number: AS7163B), in left arm for covid-19 immunisation. The patient's relevant medical history included: "borderline hypertension" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL, start date: Jan2018; METOPROLOL, start date: Jan2018; ACETYLSALICYLIC ACID, start date: Jan2018. No known allergy.  The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 25May2022, outcome "unknown", described as "Dose 1: Pfizer/Dose 2: Pfizer/Dose 3: Pfizer/Dose 4: Moderna/Dose 5: Moderna"; COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset 04Sep2023, outcome "unknown" and all described as "COVID 19 Treatment" including Paxlovid from 04Sep2023 to 09Sep2023. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (04Sep2023) Positive.
This spontaneous report as received from a registered nurse refers to an unknown number of patients of unknown ages. On an unknown date, the patients were vaccinated with improperly stored doses of PEDVAXHIB (Lot # not reported) that were exposed to 47 f for 168 hours. No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
feeling pretty sick; Jaw pain; dripping sweat; diarrhea; hot flashes; Constipation; Headache; Nausea; got fourth Covid vaccine so thought that could have increased her symptoms.; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (feeling pretty sick), PAIN IN JAW (Jaw pain), HYPERHIDROSIS (dripping sweat), DIARRHOEA (diarrhea) and HOT FLUSH (hot flashes) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TREPROSTINIL DIOLAMIN (ORENITRAM) for Pulmonary arterial hypertension.    Concurrent medical conditions included Pulmonary arterial hypertension, Palpitations, Hypotension (blood pressure machine cannot read the blood pressure maybe because too low), Hyperhidrosis, Presyncope and Hypoaesthesia. Concomitant products included AMBRISENTAN and TADALAFIL for an unknown indication.   On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and TREPROSTINIL DIOLAMIN (ORENITRAM) (Oral) 5 milligram. On an unknown date, TREPROSTINIL DIOLAMIN (ORENITRAM) (Oral) dosage was changed to 10 milligram three times a day and TREPROSTINIL DIOLAMIN (ORENITRAM) (Oral) dosage was changed to UNK, increased dose. On an unknown date, the patient experienced MALAISE (feeling pretty sick), PAIN IN JAW (Jaw pain), HYPERHIDROSIS (dripping sweat), DIARRHOEA (diarrhea), HOT FLUSH (hot flashes), CONSTIPATION (Constipation), HEADACHE (Headache), NAUSEA (Nausea) and EXTRA DOSE ADMINISTERED (got fourth Covid vaccine so thought that could have increased her symptoms.). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Headache, at an unspecified dose and frequency. At the time of the report, MALAISE (feeling pretty sick), PAIN IN JAW (Jaw pain), HYPERHIDROSIS (dripping sweat), DIARRHOEA (diarrhea) and HEADACHE (Headache) had not resolved and HOT FLUSH (hot flashes), CONSTIPATION (Constipation), NAUSEA (Nausea) and EXTRA DOSE ADMINISTERED (got fourth Covid vaccine so thought that could have increased her symptoms.) outcome was unknown.            The patient reported that she continued to have jaw pain and headaches since increased PO Orenitram to 10 mg  three times a day, and for which Tylenol did not work. The reporter's causality for the event of headache with PO Orenitram was considered to be possibly related and reporter causality was not reported  for the events of hot flush, nausea and constipation.
This spontaneous report as received from a nurse refers to multiple patients of unknown age and gender. On unknown dates, the patients were vaccinated with improperly stored doses of VAQTA for prophylaxis (lot #, expiration date, dose, route and site of administration were not reported). The temperature and time frame of excursions were unknown by reporter. There were also previous unspecified temperature excursions. The Data Logger was involved. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1706USA010657: US-009507513-1707USA000439: US-009507513-1707USA000440: US-009507513-1707USA000441: US-009507513-1707USA000442.
On 4/3/2018, patient received the Tdap vaccine. On 4/4/2018, patient woke up with her left arm swollen at the injection site, and whole body ache for 2 days, chills/ hot spells, nausea, and no appetite. By Friday, reports she felt better and was able to eat again. Today reports she only has pain at the injection site when palpating area.
Pt vaccinated with MMR/OPV developed erythematous papular rash on abdomen, face swollen, rash occured 5 days after vaccine, tx benadryl, icepacks.
Bruise at site of injection, 3 x 2 inch swollen, red area below injection site.
Around the injection site was a red bump looking like a hive the size of a half dollar. It was hot to the touch. The bump is still here as of 10/02/2011. Nothing has improved about it and it is bigger. I am taking her in if it gets bigger.
scheduled for 2nd dose and wonders if she can receive that when she is taking pain pills; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 04Aug2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunization. Relevant medical history included: "surgery" (unspecified if ongoing), notes: The surgery she had was one that was prescheduled prior to her COVID vaccine. The patient's concomitant medications were not reported. The following information was reported: PAIN (non-serious) with onset Aug2021, outcome "unknown", described as "scheduled for 2nd dose and wonders if she can receive that when she is taking pain pills". Therapeutic measures were taken as a result of pain.  Additional Information:  Patient just had a couple of questions. She got her first dose of the COVID Pfizer vaccine she thinks on 04 Aug2021 and she was supposed to have her 2nd dose today but she had surgery on Friday so she was only about 4 days postop. She asks, would it be wise to go and get her second vaccine even though she was taking pain pills. she confirmed that the surgery she had was one that was prescheduled prior to her first COVID vaccine. When attempting to inform patient that (Privacy) may have resources to speak from her question she interrupts and states, well go ahead and transfer her over there, she had been trying to get in touch with someone for the last hour. Unable to obtain further details.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever of 101°F for over twelve hours, only slightly ameliorated by acetaminophen, body aches, soreness in shoulder, dizziness, trouble walking, hot and cold periods.
Inflamed area / about 3 inches in diameter; Inflamed area that is red / about 3 inches in diameter; Area that is / hot to the touch / about 3 inches in diameter; Area that is / sore / about 3 inches in diameter; This case was reported by a consumer and described the occurrence of inflammation in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st March 2021, the patient received the 2nd dose of Shingrix. On 2nd March 2021, 1 days after receiving Shingrix, the patient experienced inflammation, erythema, feeling hot and pain. On an unknown date, the outcome of the inflammation, erythema, feeling hot and pain were unknown.   It was unknown if the reporter considered the inflammation, erythema, feeling hot and pain to be related to Shingrix.  Additional details were provided as follows: The age group was not reported, but was selected adult as per vaccine indication. The patient received second dose of shingrix on 1st March 2021. On 2nd March 2021, patient experienced inflammation, redness, feeling hot to touch and soreness in area about 3 inches in diameter that was located about 6"-8" inches from the injection site. No further information was reported.
Had an allergic reaction on his legs. He went to the dr and was dx with HSP. One leg he has a hard time walking and HSP makes your joints swell up.
on 1/14/2021 out for appointment with family. Returned cold, clammy,m lethargic, thick tongue. POx = 84% on room air. pulse = 44, BP = 110/46. Blood sugar = 120. No fever. No signs/symptoms prior to this
WITHIN 3 HOURS EYES LOOKED LIKE THEY WERE BLEEDING, NO WHITES SEEN ALONG WITH BUBBLE OF WATER ON THEM. HEART RATE WAS EXCESSIVE AND BECAME DIZZY. NOSE FELT LIKE I HAD INHALED STRONG CHEMICAL WITH BURNING AT SAME TIME. SEVERE HEADACHE. DRY COUGH. NEXT 24 HOURS SEVERE DIARRHEA.
Vaccine was expired on 01-Apr-2022, refrigerated on 04-Apr-2022 and administered on 19-Apr-2022; Vaccine was expired on 01-Apr-2022 and administered on 19-Apr-2022; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 01-Apr-2022 and administered on 19-Apr-2022) and PRODUCT STORAGE ERROR (Vaccine was expired on 01-Apr-2022, refrigerated on 04-Apr-2022 and administered on 19-Apr-2022) in a 78-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L21B) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 19-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 01-Apr-2022 and administered on 19-Apr-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was expired on 01-Apr-2022, refrigerated on 04-Apr-2022 and administered on 19-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 01-Apr-2022 and administered on 19-Apr-2022) and PRODUCT STORAGE ERROR (Vaccine was expired on 01-Apr-2022, refrigerated on 04-Apr-2022 and administered on 19-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The vial was initially stored in the refrigerator on 04-Apr-2022. The vial did not undergo any temperature excursions. It was reported that pharmacist thought that the vaccine will expire in Jun-2022, however it was expired on 01-Apr-2022.  No treatment information was reported.
Heart palpitations; sore throat; hurt when vaccination was injected; This is a spontaneous report received from a contactable other healthcare professional (who is also the patient). A 50-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3249, expiry date: unknown), intramuscular in the left arm, on 15Jan2021 16:15, at single dose, for COVID-19 immunization, in a public health clinic. The patient medical history and concomitant medications were not reported. Past drug included sulfamethoxazole, trimethoprim (BACTRIM) which the patient has allergies to. The patient did not have COVID-19 prior to vaccination and is not pregnant. The patient did not receive other vaccines in four weeks. The patient experienced heart palpitations, sore throat, and hurt when vaccination was injected on 15Jan2021 at 16:15. No treatment was given for the events. The patient was not tested for COVID-19 post vaccination. The outcome of the events was recovered on an unspecified date.
This spontaneous report as received from a registered nurse refers to 2 patients of unknown age and gender. On 19-MAY-2014 the patients were vaccinated with a dose of GARDASIL 120Y (dose, strength and route were not reported, lot # J006236, expiration date 25-FEB-2016) that was exposed to 24F for 74 hours (date of exposure unspecified). The GARDASIL was not supported by in-house temperature stability data. The reporter did not specify which dose this was for either patient in the GARDASIL series. No adverse symptoms were reported. Additional information has been requested.
Left upper arm injection site was red, swollen, hard and warm to touch. Area of erythema surrounding another area of erythema with a total measurement of 3 cm x 4 cm. 3 blisters are present. Gave 80 mg injection DEPO-MEDROL. Patient was to use cold compresses & BENADRYL.
This spontaneous initial report was received from a Nurse referring to an unspecified number of patients with not ages and genders reported. Patients medical history, concurrent conditions and concomitant medications were not reported. The nurse reported that since 05-SEP-2017, the patients were administered Improperly Stored GARDASIL 9 (strength, route of administration and dose were not reported) lot # M042853; indicated for prophylaxis.The temperature of storage was reported as 32 Fahrenheit degrees to 35 Fahrenheit degrees, for a time frame of 9 hours and 12 min. Previous temperature excursion was not reported. Digital Data logger was involved. No adverse event was reported. The outcome of the improper storage was reported as Supported. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1709USA004102:
3 days after vaccination patient started developing sores on her forehead. She said it was not painful at first but is now tender to the touch. Patient will follow up with a doctor or hospital in the morning if she is not feeling better. Told patient that if she gets signs and symptoms like swelling of the mouth or tongue, go directly to emergency room. Told patient she should follow up with a doctor because this is not a common side effect with SHINGRIX.
On 8/23/99 and 9/27/99, the pt received his 1st and 2nd Lymerix. Subsequent to his 2nd Lymerix, the pt experienced joint pain. A doctor visit was required. The most recent information, received on 5/26/00, reports the condition of the pt is unknown.
On 9/30, DOH was notified by an out-of-state health services company that a nurse had reused syringes for multiple persons earlier that day at an employee influenza vaccination clinic where the health services company had been contracted. The nurse contracted by the health services company brought three multiple-dose vials of vaccine that were intended for another event (and stored in her personal fridge without temp monitoring). The nurse reported using two syringes she found among her supplies to administer vaccine to 67 employees of the business. She reported wiping the syringes with alcohol and using a new needle for each of the 67 persons. Only 2 multiple dose vials of vaccine (10 doses/vial) were used for 67 adult participants. Participants were offered blood-borne pathogen testing (hep B, hep C, HIV), hepatitis B vaccine, and flu vaccine.
This spontaneous report as received from a physician refers to a 8 years old female patient with seasonal asthma. The patient was vaccinated with the first dose of (Merck) VARIVAX (lot# unspecified) on 30-DEC-1999 with no concomitant medications. No other co-suspects were reported. On 08-AUG-2007 the patient was diagnosed with shingles. It was noted by physician that the patient had a patch on the forehead. There is no documented culture that was done to confirm the diagnosis of shingles. The patient was treated with acyclovir (800 mg, 4 times a day for 5 days). The patient had a follow up office visit to physician on 10-AUG-2007 and the notes stated the patch was drying up and scabbing, improving and the patient was to be using NEOSPORIN. In approximately 2010, the patient had a titer done at age 12 and the results were equivocal. The outcome of the events was reported as recovered. No lab test was performed. Additional information has been requested.
Large red area, hot to the touch, onset 1-13-10. Pt seen on 1-14-10 put on Praline Syrup, pictures taken, area outlined, mother will call on 1-15-10. Talked to pt mom on 1-18-10, leg is completely cleared up.
redness, itching @ site of inj; swelling @ site of inj; general malaise; nausea;
developed fever and severely swollen lymph glands in same side of vaccine, further develoepd to same side swelling in knee 8 days later
Severe bruising at site of injection. About 5 hours later pt. felt very ill, sick to stomach.
Redness and swollen around injection site - varicella measured 6.3 x 4.2cm.
chest discomfort; This is a spontaneous report from a contactable consumer or other non hcp. A 12-year-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Batch/Lot number: unknown, Expiry Date: not reported), via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously took bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Batch/Lot number: not reported, Expiry Date: not reported), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. On an unspecified date on tuesday night, the patient experienced chest discomfort, the reporter daughter took the patient to emergency room in the hospital (further not clarified) and they give blood test (further clarification unknown) and ECG (further clarification unknown) but the patient still has the discomfort in his chest. The patient inquired was that common. The patient underwent lab tests and procedures which included blood test (unknown result, further clarification unknown) and electrocardiogram (unknown result, further clarification unknown). Outcome of the event was unknown.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up
Diagnosed with Herpes Zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On an unspecified date, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot # and expiration date were not specified) for the routine health maintenance and for the prevention of shingles. On an unspecified date after the vaccination, the patient suffered a painful rash on his arm. As a result of these symptoms, the patient presented to a medical provider and was diagnosed with Herpes Zoster. Thereafter, the patient has continued to suffer the effects of Herpes Zoster. As a result, the patient has suffered and will continue to suffer significant medical expenses, pain and suffering, and other damages.The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
Information has been received from a health professional concerning a 4 year old female who on 04 October 2004 was vaccinated subcutaneously with one dose of measles virus vaccine live (+) Mumps virus vaccine live (+) rubella virus vaccine live (Batch number HU53460). One day after vaccination on 05 October 2004, the patient developed hemiparesis and convulsions grand mal that disappeared on 07 October 2004. The patient was recovered but the events were considered to be life threatening. No further information is available. Other business partner numbers included E200603213 and 027376340.
The order of events starting at 11:00am on 12/10/2021 were: Nausea, Low Grade Fever, Vomited, Passed Out, Lost Consciousness, Unresponsive, Low/No Pulse, Blue Skin Tone. The Throwing up to losing consciousness happened within a 5 minute period. Ambulance taken from facility to a local Hospital. More Throwing Up. Monitored at hospital for hours and then sent home that night. Following up with Cardiologist and Neurologist to ensure no problems/issues.
Gave flu shot around 11:45am.  About 5 minutes later, patient got dizzy and fell while trying to sit in pharmacy waiting  room chair.  She became nauseous. I recommended they stay with me for at least 30 minutes and make sure she can walk on her own.  She fully recovered and left with her parents about 12:20pm.